- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06242509
Intestinal Akkermansia Muciniphila in Prostate Cancer (AkkPRO)
Impact of Intestinal Enrichment in Akkermansia Muciniphila by Next-generation Hormonal Therapies on Castration Resistant-prostate Cancer Response
Prostate cancer has the highest incidence and is the second leading cause of cancer death in men in western countries. Androgen deprivation therapy is the backbone treatment. However, after a latency hormone sensitive prostate cancer (HSPC) usually progresses to castration-resistant prostate cancer (CRPC) requiring treatments including next generation hormonal therapies with Abiraterone Acetate (AA). This, with limited survival.
A particularly challenging area of interest to improve outcome in cancer is the interaction between the microbiome and anti-cancer therapies. Emerging data demontrate in pre-clincal studies that prostate cancer alters the microbiota, with loss of diversity and depletion of beneficial bacteria including A. muciniphila. In the other hand, Androgen deprivation therapy, reverses these effects. Specifically, in advanced disease with castration-resistant prostate cancer (CRPC), it has been shown in small studies that Abiraterone Acetate, can modulate patient-associated gastro-intestinal microbiota through promoting the growth of A. muciniphila.
The goal of our study is to confirm that AA could promote fecal Akkermansia muciniphila growth and to use the enrichment of fecal Akkermansia muciniphila as a minimally invasive biomarker of response to AA in first line metastatic CRPC.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jérôme Lambert, Pr
- Phone Number: +33142499742
- Email: jerome.lambert@u-paris.fr
Study Contact Backup
- Name: Safae Terrisse, Dr
- Phone Number: +33142499783
- Email: safae.terrisse@aphp.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Be willing and not opposed to the study
- Be ≥ 18 years of age at the time of inclusion.
- Histologically or cytologically documented adenocarcinoma of the prostate.
- Have metastatic castration-resistant prostate cancer with castrate-level testosterone (<50 ng/dL) during the study
- Initiation of abiraterone acetate therapy or any other next-generation hormonal therapies within 15 days after inclusion
- Participants must be able and willing to comply with the study visit schedule and study procedures
- Affiliated with French social security
Exclusion Criteria:
- CRPC patients who were previously treated with any next generation hormonal therapies in a metastatic CRPC setting
- Person under legal protection
- Inability to obtain the non-opposition
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Metastatic castration resistant prostate cancer (CRPC) receiving next generation hormonal therapy
|
Plasma sampling ans stool sampling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative abundance of Akkermansia muciniphila
Time Frame: At 1 month
|
Between baseline and Month 1 of next-generation hormonotherapy (NGHT), compared between responders versus non-responders. The response is defined as an early PSA decrease > 50% at one month of NGHT. |
At 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative variation of the relative abundance of Akkermansia muciniphila
Time Frame: At 3 months
|
Between baseline and Month 3 of AA treatment, compared between responders versus non responders
|
At 3 months
|
Relative variation in PSA
Time Frame: At 1 month
|
Relative variation in PSA between baseline PSA and nadir value, according to fecal Akkermansia muciniphila enrichment
|
At 1 month
|
Receiver Operating curve (ROC)
Time Frame: At 1 month
|
Receiver Operating curve (ROC) of the baseline relative abundance of fecal Akkermansia muciniphila to predict PSA response
|
At 1 month
|
Receiver Operating curve (ROC)
Time Frame: At 3 months
|
Receiver Operating curve (ROC) of the baseline relative abundance of fecal Akkermansia muciniphila to predict PSA response
|
At 3 months
|
PSA progression-free (PSA-PFS) survival
Time Frame: At 3 months
|
According to fecal Akkermansia muciniphila baseline relative abundance.
PSA-PFS will be defined as the time from treatment initiation to PSA progression as per PCWG3 (The Prostate Cancer Working Group 3) or death, whichever occurs first; patients without event at M3 will be treated as censored observations.
|
At 3 months
|
Anti- Akkermansia muciniphila IgG levels
Time Frame: At baseline
|
At baseline
|
|
Anti- Akkermansia muciniphila IgG levels
Time Frame: At 1 month
|
At 1 month
|
|
Anti- Akkermansia muciniphila IgG levels
Time Frame: At 3 months
|
At 3 months
|
|
Anti- Akkermansia muciniphila IgA levels
Time Frame: At baseline
|
At baseline
|
|
Anti- Akkermansia muciniphila IgA levels
Time Frame: At 1 month
|
At 1 month
|
|
Anti- Akkermansia muciniphila IgA levels
Time Frame: At 3 months
|
At 3 months
|
|
Alpha diversity
Time Frame: At baseline
|
Assessed by Shannon index (Microbial Richness)
|
At baseline
|
Alpha diversity
Time Frame: At 1 month
|
Assessed by Shannon index (Microbial Richness)
|
At 1 month
|
Alpha diversity
Time Frame: At 3 months
|
Assessed by Shannon index (Microbial Richness)
|
At 3 months
|
Beta diversity
Time Frame: At baseline
|
Assessed by Bray-Curtis dissimilarity (Microbial Diversity)
|
At baseline
|
Beta diversity
Time Frame: At 1 month
|
Assessed by Bray-Curtis dissimilarity (Microbial Diversity)
|
At 1 month
|
Beta diversity
Time Frame: At 3 months
|
Assessed by Bray-Curtis dissimilarity (Microbial Diversity)
|
At 3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP221176
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-resistant Prostate Cancer
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Rohan GarjeJanssen Scientific Affairs, LLCNot yet recruitingCastration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
Clinical Trials on Biological samples
-
Imagine InstituteReference center for rare diseases (Rare Gynecologic Diseases)RecruitingMayer Rokitansky Kuster Hauser SyndromeFrance
-
Yale UniversityRoche-GenentechRecruiting
-
Rennes University HospitalCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
University Hospital, MontpellierCompletedCOVID-19 | Rheumatic Diseases | SARS-CoV InfectionFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruiting
-
University of LorraineRecruitingQuality of Life | Chronic Pain | Resilience, Psychological | Adverse Childhood Experiences | Chronic Stress | Attachment Styles | Epigenesis, GeneticFrance
-
Centre Hospitalier Universitaire de NiceFrench Society of RheumatologyRecruiting
-
Centre Hospitalier Universitaire de BesanconCompleted
-
Centre Hospitalier Universitaire de BesanconCompletedChronic Myeloid LeukemiaFrance